OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
Emily K. Kleczko, Trista K. Hinz, Teresa T. Nguyen, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 14
Emily K. Kleczko, Trista K. Hinz, Teresa T. Nguyen, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 14
Showing 14 citing articles:
Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect
Conghua Lu, Ziyuan Gao, Di Wu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009165-e009165
Open Access | Times Cited: 10
Conghua Lu, Ziyuan Gao, Di Wu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009165-e009165
Open Access | Times Cited: 10
Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response
Emily K. Kleczko, Anh T. Le, Trista K. Hinz, et al.
Cancer Letters (2023) Vol. 556, pp. 216062-216062
Open Access | Times Cited: 17
Emily K. Kleczko, Anh T. Le, Trista K. Hinz, et al.
Cancer Letters (2023) Vol. 556, pp. 216062-216062
Open Access | Times Cited: 17
Ensartinib as a neoadjuvant therapy for stage IIIA non-small cell lung cancer patients with EML4-ALK fusion: a case report and literature review
Hao Zhang, Wei Xia, Yifan Zhang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Hao Zhang, Wei Xia, Yifan Zhang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
Daniel J Sisler, Trista K. Hinz, Anh‐Tuan Le, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Daniel J Sisler, Trista K. Hinz, Anh‐Tuan Le, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications
Marco Sposito, Serena Eccher, Luca Pasqualin, et al.
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 8, pp. 959-970
Closed Access | Times Cited: 2
Marco Sposito, Serena Eccher, Luca Pasqualin, et al.
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 8, pp. 959-970
Closed Access | Times Cited: 2
Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis
David O’Reilly, Caroline L. O’Leary, Aislinn Reilly, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
David O’Reilly, Caroline L. O’Leary, Aislinn Reilly, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Targeting therapy-persistent residual disease
Xiaoxiao Sun, Lani F. Wu, Steven J. Altschuler, et al.
Nature Cancer (2024)
Closed Access | Times Cited: 2
Xiaoxiao Sun, Lani F. Wu, Steven J. Altschuler, et al.
Nature Cancer (2024)
Closed Access | Times Cited: 2
Upregulation of complement proteins in lung cancer cells mediates tumor progression
Emily K. Kleczko, Joanna M. Poczobutt, Andre Navarro, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 6
Emily K. Kleczko, Joanna M. Poczobutt, Andre Navarro, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 6
Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions
Erin L. Schenk
Translational Lung Cancer Research (2023) Vol. 12, Iss. 2, pp. 322-336
Open Access | Times Cited: 6
Erin L. Schenk
Translational Lung Cancer Research (2023) Vol. 12, Iss. 2, pp. 322-336
Open Access | Times Cited: 6
Inflammation promotes aging-associated oncogenesis in the lung
Catherine Pham‐Danis, Shi Biao Chia, Hannah A. Scarborough, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Catherine Pham‐Danis, Shi Biao Chia, Hannah A. Scarborough, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes
Laura Schubert, Anh‐Tuan Le, Trista K. Hinz, et al.
Biology Open (2023) Vol. 12, Iss. 8
Open Access | Times Cited: 2
Laura Schubert, Anh‐Tuan Le, Trista K. Hinz, et al.
Biology Open (2023) Vol. 12, Iss. 8
Open Access | Times Cited: 2
Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer
Annkristin Heine, Stefanie Andrea Erika Held, Solveig Nora Daecke, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Annkristin Heine, Stefanie Andrea Erika Held, Solveig Nora Daecke, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Inflammation Promotes Aging‐Associated Oncogenesis in the Lung
Catherine Pham‐Danis, Shi B. Chia, Hannah A. Scarborough, et al.
Aging and Cancer (2024)
Open Access
Catherine Pham‐Danis, Shi B. Chia, Hannah A. Scarborough, et al.
Aging and Cancer (2024)
Open Access
A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes
Laura Schubert, Anh‐Tuan Le, Trista K. Hinz, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Laura Schubert, Anh‐Tuan Le, Trista K. Hinz, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
